CA2973119A1 - Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof - Google Patents

Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof Download PDF

Info

Publication number
CA2973119A1
CA2973119A1 CA2973119A CA2973119A CA2973119A1 CA 2973119 A1 CA2973119 A1 CA 2973119A1 CA 2973119 A CA2973119 A CA 2973119A CA 2973119 A CA2973119 A CA 2973119A CA 2973119 A1 CA2973119 A1 CA 2973119A1
Authority
CA
Canada
Prior art keywords
hcv
cells
hadsc
hadscs
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2973119A
Other languages
English (en)
French (fr)
Inventor
Chen-Lung Lin
Original Assignee
Frontier Bio-Drug Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Bio-Drug Development Ltd filed Critical Frontier Bio-Drug Development Ltd
Publication of CA2973119A1 publication Critical patent/CA2973119A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2973119A 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof Abandoned CA2973119A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/070243 WO2016109947A1 (en) 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Publications (1)

Publication Number Publication Date
CA2973119A1 true CA2973119A1 (en) 2016-07-14

Family

ID=56355408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2973119A Abandoned CA2973119A1 (en) 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Country Status (10)

Country Link
US (1) US10273461B2 (https=)
EP (1) EP3242932A4 (https=)
JP (1) JP6670322B2 (https=)
KR (1) KR20170101998A (https=)
CN (1) CN107208060B (https=)
AU (1) AU2015376561A1 (https=)
CA (1) CA2973119A1 (https=)
HK (1) HK1246824A1 (https=)
TW (1) TWI616528B (https=)
WO (1) WO2016109947A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
IL278473A (en) 2020-11-03 2022-06-01 Yeda Res & Dev Methods for diagnosing and determining treatment in multiple myeloma
CN114686517A (zh) * 2020-12-25 2022-07-01 中国医学科学院病原生物学研究所 一种hcv四受体转基因合并stat1敲除小鼠的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786207A (en) 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
CA2312847C (en) 1997-12-02 2014-09-30 Zen Bio, Inc. Differentiation of adipose stromal cells into osteoblasts and uses thereof
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050076396A1 (en) 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
JP2009153383A (ja) * 2006-04-03 2009-07-16 Eci Inc 成熟肝細胞様細胞の製造方法
KR101224504B1 (ko) * 2010-10-01 2013-01-22 가톨릭대학교 산학협력단 크립토탄신온의 신규 용도
GB201119335D0 (en) * 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
US20140179775A1 (en) * 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US9402710B2 (en) * 2012-07-16 2016-08-02 The Board Of Trustees For The Leland Stanford Junior University Macroporous 3-D scaffolds for tissue engineering

Also Published As

Publication number Publication date
US10273461B2 (en) 2019-04-30
WO2016109947A1 (en) 2016-07-14
TW201625786A (zh) 2016-07-16
HK1246824A1 (zh) 2018-09-14
EP3242932A1 (en) 2017-11-15
JP6670322B2 (ja) 2020-03-18
CN107208060A (zh) 2017-09-26
JP2018501820A (ja) 2018-01-25
AU2015376561A1 (en) 2017-07-27
TWI616528B (zh) 2018-03-01
CN107208060B (zh) 2021-06-18
EP3242932A4 (en) 2018-05-30
US20180023058A1 (en) 2018-01-25
KR20170101998A (ko) 2017-09-06

Similar Documents

Publication Publication Date Title
Roelandt et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
Chen et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture
Sanada et al. Transmission of HBV DNA mediated by ceramide-triggered extracellular vesicles
Yuan et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection
Nourbakhsh et al. Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production
Florimond et al. Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication
Guan et al. Caveolin-1 is essential in the differentiation of human adipose-derived stem cells into hepatocyte-like cells via an MAPK pathway-dependent mechanism
US10273461B2 (en) Employing human adipose-derived stem cells to propagate serum-derived hepatitis C virus and use thereof
Banaudha et al. Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis
Boyer et al. TM6SF2 promotes lipidation and secretion of hepatitis C virus in infected hepatocytes
Kajimoto et al. Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues
Lu et al. Tree shrew bone marrow–derived mesenchymal stem cells express CD81, OCLN, and miR‐122, facilitating the entire hepatitis C virus life cycle
Maggi et al. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
CN106148337A (zh) 长非编码rna ay927503及其用途
Li et al. Mouse mesenchymal stem cells from bone marrow differentiate into smooth muscle cells by induction of plaque-derived smooth muscle cells
Pewkliang et al. Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection
CN100500836C (zh) Hcv病毒体外培养方法
Galsinh The role of stromal cells in Hepatitis C virus infection
Habermann Hepatitis C virus infection of human hepatocyte organoids
Couteaudier et al. Hypoxia-inducible factor 2 triggers the production of highly infectious native-like hepatitis C virus particles: Couteaudier et al.
Sargiacomo Role of NTCP in HBV infection of mesenchymal stem cells derived hepatocytes and relevance of its ontogenesis for liver diseases
Meuleman et al. 861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO
Beer Hepatocellular lipid metabolism in Hepatitis C virus infection
Barnes The tetraspanin CD81 dynamics: investigating the role in hepatitis C virus entry
US20060183111A1 (en) Primary human hepatocytes for native hepatitis C virus (HCV) replication

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831